• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Acridine Derivative Topical Cool Drug Monograph Documentation Sheet Extravasation Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Legha SS, Gutterman JU, Hall SW, et al: Phase I clinical investigation of 4’(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 38: 3712–3716, 1978.PubMedGoogle Scholar
  2. [2]
    Soble MJ, Dorr RT, Plezia P, et al: Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemother Pharmacol 20: 33–36, 1987.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [3]
    Dorr RT: Extravasation of vesicant antineoplastics: clinical and experimental findings. Ariz Med 38: 271–275, 1981.PubMedGoogle Scholar
  2. [4]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  3. [5]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  4. [6]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  5. [7]
    Louie AC, Issell BF: Amsacrine (AMSA) — a clinical review. J Clin Oncol 3: 562–592, 1985.PubMedGoogle Scholar
  6. [8]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  7. [9]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.Google Scholar
  8. [10]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  9. [11]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  10. [12]
    Dorr RT, Von Hoff DD: Drug monographs: amsacrine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 182–189, 1994.Google Scholar
  11. [13]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  12. [14]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  13. [15]
    Summary of product characteristics Amsidyl® (Germany), Gödecke, November 1996Google Scholar
  14. [16]
    Allwood M: Chemotherapeutic agents: amsacrine. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 186–188, 1997.Google Scholar

Further reading

  1. Henry MC, Port CD, Levine BS: Preclinical toxicologic evaluation of 4’-(9acridinylamino)methanesulfon-m-anisidide (AMSA) in mice, dogs, and monkeys. Cancer Treat Rep 64: 855–860, 1980.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations